Stuck on a biologic denial?
Ask us about the request, the claim or the appeal. A real person replies within one business day.
Contact usMost biologic denials are paperwork failures, not clinical disagreements. A prior authorization is denied before the dose when the request lacks something the payer’s policy lists, such as labs, step therapy history or the right prescriber. A claim is denied after the dose when the units, NDC, modifier, diagnosis or dates do not match. Check both before the patient is in the chair, and appeal the rest on the payer’s clock.
Where biologic denials happen
A biologic can be refused at two points. Before the dose, the payer checks the prior authorization request against its written policy for the drug. After the dose, its claim system checks the claim against the authorization, coding rules and edits. Under buy and bill, the second kind costs more, because the practice has already bought the drug.
- Benefit check
-
Gate 1Prior authorization Labs,Step therapy,Prescriber,Site of care,Quantity Denied?Appeal
- Dose givenThe practice has already bought the drug
-
Gate 2Claim Units,NDC,JZ or JW,Diagnosis,Administration code,Dates,Frequency Denied?Correct or appeal
-
Paid
Much of the first kind is avoidable. A study of asthma biologic prescriptions at Montefiore and Scripps, published in January 2023, recorded the reasons insurers gave for 48 denials:
Sehanobish et al., J Allergy Clin Immunol Global, 2023. Prescriptions from 2018 to 2020.
| Denial reason | Where | How to prevent it |
|---|---|---|
| No authorization, or it expired | Prior auth,Claim | Track each authorization’s dates and doses left; renew before the last one. |
| Step therapy not documented | Prior auth | Chart each prior controller with dose, dates and outcome. |
| Labs missing or out of date | Prior auth | Attach the dated lab the policy names: eosinophils, total IgE, allergen testing. |
| Prescriber specialty not accepted | Prior auth | Submit under a specialist the policy lists. |
| Quantity or frequency over the limit | Prior auth,Claim | Match the label and the policy, or request an exception. |
| Site-of-care or home-administration rule | Prior auth | Check the plan’s rule; document why the office is needed. |
| Medical vs pharmacy benefit mismatch | Benefit check | Confirm which benefit covers this drug in this setting. |
| Eligibility or coordination of benefits | Benefit check,Claim | Re-verify coverage and payer order before every dose. |
| HCPCS units wrong | Claim | Dose divided by the code’s billing unit. |
| NDC missing, misformatted or wrong unit | Claim | 11 digits, N4 qualifier, unit qualifier and quantity; NDC active on the date of service. |
| JZ or JW missing | Claim | JZ when nothing is discarded; a JW line for the discard. |
| Diagnosis not specific enough | Claim | Use the codes the policy lists. |
| Administration code missing or mismatched | Claim | Bill the administration that matches the route. |
| Date outside the authorization | Claim | Check the date against the window before submitting. |
| Duplicate or frequency edit | Claim | Check the last paid date and the code’s unit limits. |
Before the dose: prior authorization denials
Payer policies for asthma and allergy biologics read like checklists, and a request is denied when any line is unproven. UnitedHealthcare’s commercial Fasenra policy, effective October 1, 2026, is typical:
What the policy asks for
UnitedHealthcare,Fasenra,Oct 1, 2026
- Severe asthma that is uncontrolled: ACT below 20, two steroid bursts in 12 months, an emergency visit, or reduced FEV1
- Baseline blood eosinophils of at least 150 cells/µL
- A maximally dosed inhaled steroid combination
- No second asthma biologic
- Dosing per the label
- A pulmonologist or allergist/immunologist prescribing
- First approval of no more than 12 months
The same insurer’s Xolair policy adds a baseline total IgE of 30 to 1,300 IU/mL and a positive test to a year-round allergen.
Four points a policy table does not show:
- Renewals need proof of response: fewer exacerbations, less rescue use, better FEV1 or fewer symptoms, documented before the approval runs out.
- Medicare Advantage limits step therapy for Part B drugs to new starts, with a look-back of at least 365 days.
- Home-administration rules are spreading. In April 2025, Blue Cross and Blue Shield plans in Illinois, Texas, Oklahoma, New Mexico and Montana began requiring commercial members to self-administer Fasenra, Tezspire, Nucala and Xolair at home unless the provider gets prior approval.
- The benefit decides the door. UnitedHealthcare covers office-given Xolair under the medical benefit and self-injected Xolair under the pharmacy benefit. A request sent to the wrong benefit fails.
After the dose: claim denials
Units. A J-code covers a fixed amount of drug. Omalizumab (J2357) is per 5 mg; mepolizumab (J2182), benralizumab (J0517) and tezepelumab (J2356) are per 1 mg. Medicare also caps the units of a code per patient per day.
NDC. Commercial and Medicaid payers commonly require the National Drug Code, and Medicaid uses it to invoice manufacturer rebates on office-given drugs. NDC units are not HCPCS units, and a claim fails when the two do not reconcile.
JZ and JW. For a separately payable Medicare Part B drug from a single-dose container:
- Nothing discarded: one line with the units given and JZ, required since July 1, 2023.
- Some discarded: one line for the units given with no modifier, and one line for the discarded units with JW, required since January 1, 2017. Record the discarded amount in the chart.
- Since October 1, 2023, claims without the right modifier may be returned unprocessed until corrected.
- Neither applies to multiple-dose containers, rural health clinics, federally qualified health centers or overfill. A dose below one billing unit is billed as the full unit with JZ.
Had both vials been used in full (300 mg), it would be one line: J2357-JZ × 60.
Diagnosis, administration and dates. Code the diagnosis to the specificity the policy lists; UnitedHealthcare’s asthma IL-5 policy names J45.50 to J45.52 (severe persistent asthma) and J82.83 (eosinophilic asthma). Bill the administration that matches the route, for example CPT 96372 for a subcutaneous injection. A dose given a day after the authorization ends, or sooner than the labeled interval, is denied even when the patient is approved. Other payers set their own modifier rules, so check each one.
A pre-dose checklist for every biologic
Before the request
- 1. Verify eligibility and the benefit: coverage on the date of service, which plan is primary, medical or pharmacy benefit. Note the plan type; it sets the appeal path.
- 2. Pull the payer’s current drug policy and save the version you used.
- 3. Match the chart to the policy line by line: diagnosis code, severity, dated labs, prior therapies, prescriber specialty, dose and interval.
- 4. Submit with everything attached, so the reviewer has no reason to ask for more.
When it is approved
- 5. Record the approval: number, drug, units, doses, start and end dates, site of care.
Every dose
- 6. Recheck the date against the window, the doses left and the coverage.
- 7. Document the administration: NDC, lot, dose given and any discard by vial.
- 8. Build the claim from the record: units, NDC with qualifier and quantity, JZ or JW, diagnosis, administration code, authorization number.
Before it runs out
- 9. Start the renewal early, with response data, before the last approved dose.
Our own version of this list is in what we check before a biologic claim.
How to appeal a biologic denial
Read the denial notice first; it gives the reason, the level and the deadline.
Correct, don’t appeal
A claim returned unprocessed for a missing modifier or NDC is corrected and resubmitted. In Original Medicare, minor clerical errors go through a reopening.
Peer-to-peer
The prescriber talks to the plan’s reviewer. It is informal and does not pause the appeal deadline. In an AMA survey, 16% of physicians said the reviewer often or always had the right qualifications.
| Coverage | First appeal | Decision | Next levels |
|---|---|---|---|
| Commercial | Internal appeal; group plans must allow at least 180 days | 30 days before service, 60 days after; urgent 72 hours | External review: ask within 4 months; decision within 45 days, or 72 hours if expedited |
| Medicare Advantage | Plan reconsideration within 65 days of the notice | Part B drug: 7 days, or 72 hours expedited; payment 60 days | Automatic independent review; then a judge ($200 in 2026), the Appeals Council, federal court ($1,960) |
| Original Medicare | Redetermination by the contractor within 120 days of receipt | Generally 60 days | Reconsideration within 180 days; then a judge, the Council, court |
In Medicare Advantage, the plan’s first decision on a Part B drug request is due within 72 hours, or 24 if expedited, and a physician’s request to expedite a reconsideration must be honored.
- 01Patient, member ID and plan; for an appeal, the denial reference and date
- 02Drug, HCPCS code, NDC, dose, route, interval, site of care and doses requested
- 03ICD-10 diagnosis at the policy’s specificity
- 04Severity with dates: exacerbations, steroid bursts, emergency visits or admissions, control scores, lung function
- 05The labs the policy names, with values and dates, marked pre-treatment where relevant
- 06Each prior therapy with dose, dates, adherence and outcome, or the contraindication
- 07The FDA-labeled indication and the relevant clinical guideline
- 08For a renewal, the measured response
- 09For an appeal, the stated denial reason quoted and answered, with page references
- 10Any reason to expedite
- 11Prescriber name, specialty, NPI, signature and a number for a peer-to-peer
What changed in 2025 and 2026
- June 23, 2025The insurer pledgePlans covering what AHIP called 257 million Americans committed to narrow medical prior authorization by January 1, 2026, honor an existing approval for 90 days after a plan change, explain denials clearly, and answer 80% of electronic approvals in real time in 2027. In an AMA survey released May 13, 2026, 33% of physicians expected it to make a meaningful difference.
- September 1, 2025Texas widens its gold cardTexas exempts physicians from a state-regulated plan’s prior authorization for a service when at least 90% of their requests were approved; fewer than 4% had qualified. HB 3812 lengthened the review period to 12 months and set a five-request minimum. Arkansas, Colorado, Louisiana, West Virginia and Wyoming also had gold-card laws before 2025.
- January 1, 2026The CMS prior authorization rule’s clocks start, without drugsCMS-0057-F covers Medicare Advantage, Medicaid, CHIP and plans on the federal exchanges. All but the exchange plans must now decide within 72 hours (expedited) or 7 days (standard), and all must give a specific denial reason. In Medicare Advantage, “drugs” means any and all drugs the plan covers, so office-given biologics fall outside the new clocks, the denial-reason rule and the public metrics. The same day, CMS’s WISeR model began adding prior authorization in Original Medicare for selected services in six states; biologics are not among CMS’s examples.
- April 2026proposedA version for drugsCMS-0062-P would extend electronic prior authorization and faster decisions to drugs, including medical-benefit drugs, mostly from October 1, 2027, with drug metrics from 2028. Comments closed June 15, 2026. As of October 19, 2026 it is not final.
What the denial and appeal numbers say
None of these figures is specific to biologics, but the pattern holds across every source: few denials are appealed, and most appeals succeed.
KFF, January 2026.
| Market | Standard requests denied | Overturned on appeal |
|---|---|---|
| Medicare Advantage | ||
| Medicaid managed care | ||
| Marketplace |
13%
of sampled Medicare Advantage prior authorization denials met Medicare rules anyway (HHS-OIG, 2022)
40 a week
prior authorizations per physician, taking 13 hours of physician and staff time (AMA, 2026)
Where Medico fits
Our Biologics Management team runs benefit checks, prior authorizations and buy and bill for member practices, which covers the before-the-dose work above. Members can also model a biologic’s cost and reimbursement before stocking it.
Medico Billing, with Nadia, builds and checks every claim before it is filed: units, NDC, modifiers, diagnosis and authorization dates.
Questions and answers
What is the most common reason a biologic prior authorization is denied?
Missing information. In a two-center asthma study, the top reason was that no additional clinical information was provided, 41.7% of 48 denials. Sending the labs, therapy history and severity evidence the policy lists with the first request prevents most of these.
Does the CMS prior authorization rule (CMS-0057-F) cover biologics?
No. Its decision clocks, denial-reason rule and public metrics exclude drugs, including office-given ones. CMS proposed covering drugs in CMS-0062-P in April 2026, mostly from October 1, 2027, but that rule is not final.
What happens if a Medicare biologic claim is missing JZ or JW?
For a separately payable drug from a single-dose container, it may be returned unprocessed. Correct it and resubmit: JZ when nothing was discarded, or a separate JW line for the discarded units.
How long do we have to appeal a denied biologic?
Commercial group plans must allow at least 180 days, Medicare Advantage allows 65 days from the notice date, and Original Medicare allows 120 days from receipt. The denial notice states the deadline that applies.
Is a peer-to-peer review the same as an appeal?
No. It is an informal call between the prescriber and the plan’s reviewer. It can reverse a denial quickly, but it does not pause the appeal deadline.
What should a letter of medical necessity for a biologic include?
The drug, code, dose and interval; the diagnosis code; dated severity evidence and labs; each prior therapy and its outcome; the labeled indication; and, for an appeal, a direct answer to the stated denial reason, in the order of the payer’s criteria.
How often are prior authorization denials overturned on appeal?
In Medicare Advantage, 80.7% of appealed prior authorization denials were fully or partly overturned in 2024. Insurers’ own 2025 metrics, which exclude drugs, show 43% to 67% depending on the market.
Sources
- 01Sehanobish E, et al. Elaborate biologic approval process delays care of patients with moderate-to-severe asthma, J Allergy Clin Immunol Global, January 2023
- 02Discarded Drugs and Biologicals: JW and JZ Modifier Policy FAQs, CMS, December 2025
- 03Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet, CMS, January 17, 2024
- 0442 CFR Part 422: Medicare Advantage prior authorization, step therapy and appeals, eCFR
- 05Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P), CMS, April 10, 2026
- 06Health plans take action to simplify prior authorization, AHIP, June 23, 2025
- 07Prior authorization reform pledge falls short with physicians, American Medical Association, May 13, 2026
- 08WISeR Model, CMS Innovation Center
- 092025 legislative wrap-up: gold card law refinements, Texas Medical Association, 2025
- 10Prior authorization reform gains momentum in states, MultiState, August 14, 2025
- 11Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, KFF, January 28, 2026
- 12Prior authorization metrics provide new insights into insurer practices, KFF, August 13, 2026
- 13Some Medicare Advantage denials of prior authorization requests raise concerns, HHS-OIG, April 27, 2022
- 1445 CFR 147.136, internal claims and appeals and external review, eCFR
- 1529 CFR 2560.503-1, ERISA claims procedure, eCFR
- 16Reconsideration by the Medicare Advantage plan, CMS
- 17First level of appeal: redetermination by a Medicare contractor, CMS
- 18Medicare appeals: amount in controversy thresholds for 2026, Federal Register, December 4, 2025
- 19Respiratory Interleukin-5 Inhibitor policy, UnitedHealthcare Commercial, effective October 1, 2026
- 20Xolair (omalizumab) policy, UnitedHealthcare Commercial, effective October 1, 2025
- 21Blue Cross Blue Shield now requires prior approval for severe asthma drugs in some states, Stateline, April 15, 2025
- 22Coding guidelines for drug-related medical claims, Cigna
- 23Medicare NCCI Medically Unlikely Edits, CMS
